---
schema_version: "secwatch.filing_event.v1"
accession: "0001453687-25-000077"
form_type: "8-K"
ticker: "RNAC"
cik: "0001453687"
company_name: "Cartesian Therapeutics, Inc."
filed_at: "2025-04-29T23:59:59+00:00"
generated_at: "2026-05-23T03:41:09.805910+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Cartesian Therapeutics CTO Metin Kurtoglu to depart May 1; will serve as consultant through April 2026

## Summary
- CTO Metin Kurtoglu's employment ends May 1, 2025; consulting agreement runs through April 30, 2026.
- Separation agreement includes 12 months salary, pro-rated bonus eligibility, and accelerated vesting of equity awards granted Jan 2, 2024.
- Release of claims upon receipt of severance benefits as per employment agreement dated March 28, 2024.
- No replacement named; Dr. Kurtoglu will remain in advisory role under consulting terms.

## SEC filing metadata
- accession: 0001453687-25-000077
- form_type: 8-K
- ticker: RNAC
- cik: 0001453687
- company_name: Cartesian Therapeutics, Inc.
- filed_at: 2025-04-29T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.5
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1453687/000145368725000077/0001453687-25-000077-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1453687/000145368725000077/rnac-20250429.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001453687-25-000077
- JSON: https://secwatch.observer/filing/0001453687-25-000077.json
- Plain text: https://secwatch.observer/filing/0001453687-25-000077.txt

## Source-grounded claims
- claim_id: 43b4aa7367
  claim: Metin Kurtoglu departed as Chief Technology Officer at Cartesian Therapeutics, Inc..
  evidence_excerpt: Dr. Kurtoglu’s employment with the Company will end effective May 1, 2025
  evidence_url: https://www.sec.gov/Archives/edgar/data/1453687/000145368725000077/0001453687-25-000077-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.